Mizuno Takuro, Mizuno Shigeru, Kanda Tsugiyasu
Department of Community Medicine, Kanazawa Medical University Himi Municipal Hospital, Himi, Toyama, Japan.
Mizuno Clinic, Osaka, Japan.
PLoS One. 2014 Apr 3;9(4):e92601. doi: 10.1371/journal.pone.0092601. eCollection 2014.
Evidence of the effectiveness of influenza vaccination in children and elderly adults is limited, although this population has the highest risk for influenza infection.
We enrolled 4443 participants, aged 3-97 years, who had influenza-kit-positive results during seasons 2007-12, including 2135 with influenza A, 534 with A/H1N1, and 1643 with influenza B. Eligible subjects completed a questionnaire to identify past influenza infection and vaccination history. For the diagnosis of current influenza infection, subjects were examined, and pharyngeal swabs were collected and tested using the Capilia flu rapid diagnosis kit to confirm influenza infection. An interim analysis was performed using clinician-based surveillance data for the entire four seasons of influenza infection in Japan.
In 3035 adults aged 14-64 years, administration of the influenza vaccine significantly reduced the frequency of infection (P<0.01) in the 2008 and 2010 seasons, but not in the 2009 and 2011 seasons. Moreover, the vaccine did not reduce the frequency of infection in children (aged <13 years) and older adults (aged >65 years) significantly. Laninamivir, oseltamivir phosphate, zanamivir hydrate, and amantadine hydrochloride were administered to 1381, 2432, 1044, and 100 patients, respectively. They were effective in >97% of patients, with no significant differences being found. Adverse effects were few. However, the recurrence rate of influenza infection after treatment was significantly reduced in patients who received laninamivir compared with that in those who received oseltamivir and zanamivir (P<0.01). The effectiveness of laninamivirdid not decrease.
The vaccines administered had limited efficacy in reducing the frequency of influenza infection in young adults. Laninamivir significantly reduced the recurrence of influenza infection when compared with other neuraminidase inhibitors.
尽管儿童和老年人是流感感染风险最高的人群,但流感疫苗在这两类人群中有效性的证据有限。
我们招募了4443名年龄在3至97岁之间、在2007年至2012年流感季节流感检测试剂盒呈阳性结果的参与者,其中包括2135例甲型流感、534例甲型H1N1流感和1643例乙型流感。符合条件的受试者填写问卷以确定既往流感感染和疫苗接种史。为诊断当前流感感染,对受试者进行检查,并采集咽拭子,使用卡匹拉流感快速诊断试剂盒进行检测以确认流感感染。使用日本流感感染四个季节基于临床医生的监测数据进行中期分析。
在3035名年龄在14至64岁的成年人中,接种流感疫苗在2008年和2010年季节显著降低了感染频率(P<0.01),但在2009年和2011年季节没有降低。此外,疫苗在儿童(年龄<13岁)和老年人(年龄>65岁)中未显著降低感染频率。分别有1381例、2432例、1044例和100例患者接受了拉尼米韦、磷酸奥司他韦、扎那米韦水合物和盐酸金刚烷胺治疗。它们在>97%的患者中有效,未发现显著差异。不良反应很少。然而,与接受磷酸奥司他韦和扎那米韦的患者相比,接受拉尼米韦治疗的患者流感感染治疗后的复发率显著降低(P<0.01)。拉尼米韦的有效性未降低。
所接种的疫苗在降低年轻人流感感染频率方面疗效有限。与其他神经氨酸酶抑制剂相比,拉尼米韦显著降低了流感感染的复发率。